home / stock / cgen / cgen quote
Last: | $1.77 |
---|---|
Change Percent: | 1.14% |
Open: | $1.74 |
Close: | $1.77 |
High: | $1.79 |
Low: | $1.72 |
Volume: | 117,308 |
Last Trade Date Time: | 07/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.77 | $1.74 | $1.77 | $1.79 | $1.72 | 117,308 | 07-26-2024 |
$1.76 | $1.77 | $1.76 | $1.77 | $1.71 | 185,972 | 07-25-2024 |
$1.75 | $1.83 | $1.75 | $1.86 | $1.725 | 219,915 | 07-24-2024 |
$1.85 | $1.82 | $1.85 | $1.8603 | $1.82 | 86,268 | 07-23-2024 |
$1.82 | $1.83 | $1.82 | $1.83 | $1.73 | 222,433 | 07-22-2024 |
$1.82 | $1.9 | $1.82 | $1.9 | $1.75 | 277,708 | 07-19-2024 |
$1.87 | $1.87 | $1.87 | $1.96 | $1.8401 | 277,021 | 07-18-2024 |
$1.86 | $1.85 | $1.86 | $1.8879 | $1.8001 | 168,863 | 07-17-2024 |
$1.87 | $1.94 | $1.87 | $1.94 | $1.84 | 392,094 | 07-16-2024 |
$1.91 | $1.78 | $1.91 | $2.05 | $1.76 | 791,156 | 07-15-2024 |
$1.76 | $1.83 | $1.76 | $1.855 | $1.75 | 251,949 | 07-12-2024 |
$1.75 | $1.72 | $1.75 | $1.81 | $1.72 | 279,340 | 07-11-2024 |
$1.72 | $1.76 | $1.72 | $1.76 | $1.6744 | 138,618 | 07-10-2024 |
$1.76 | $1.75 | $1.76 | $1.77 | $1.6806 | 146,344 | 07-09-2024 |
$1.71 | $1.58 | $1.71 | $1.75 | $1.58 | 224,539 | 07-08-2024 |
$1.56 | $1.61 | $1.56 | $1.625 | $1.5 | 813,133 | 07-05-2024 |
$1.67 | $1.72 | $1.67 | $1.72 | $1.59 | 303,356 | 07-04-2024 |
$1.67 | $1.72 | $1.67 | $1.72 | $1.59 | 303,356 | 07-03-2024 |
$1.69 | $1.75 | $1.69 | $1.75 | $1.68 | 144,921 | 07-02-2024 |
$1.75 | $1.73 | $1.75 | $1.78 | $1.72 | 141,732 | 07-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...
Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig PR Newswire Phase 3 trial evaluating rilvegostomig as monotherapy and in combination with AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...